MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Topic
Endometrial and Cervical Cancer Treatments
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

1,989 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
1,989 works in the cohort · of 4,299,418page 1 of 40

Labels cover 4 of 1,989 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 1,989 of 1,989 works in this cohort. Predictions are machine_predicted_unvalidated teacher distillation outputs. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
Endometrial cancer
2022· article· en· The Lancet· Medicine
distilled prediction:candidate · insufficient_payloadconsensus · none
1,291
citations
affunlabeled
Type I and II Endometrial Cancers: Have They Different Risk Factors?
Veronica Wendy Setiawan, Hannah Yang, Malcolm C. Pike, Susan E. McCann, Herbert Yu, Yong‐Bing Xiang +55 more
2013· review· en· Journal of Clinical Oncology· Medicine
distilled prediction:candidate · metaresearch+research_integrityconsensus · none
833
citations
affunlabeled
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
Mansoor Raza Mirza, Dana M. Chase, Brian M. Slomovitz, René dePont Christensen, Zoltán Novàk, Destin Black +25 more
2023· article· en· New England Journal of Medicine· Medicine
distilled prediction:candidate · noneconsensus · none
800
citations
affno abstractunlabeled
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer
Nicoletta Colombo, Carien L. Creutzberg, Frédéric Amant, Tjalling Bosse, Antonio González-Martı́n, Jonathan A. Ledermann +5 more
2015· article· en· International Journal of Gynecological Cancer· Medicine
distilled prediction:candidate · insufficient_payloadconsensus · none
757
citations
affunlabeled
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
Ramez N. Eskander, Michael W. Sill, Lindsey Beffa, Richard G. Moore, Joanie M. Hope, Fernanda Musa +21 more
2023· article· en· New England Journal of Medicine· Medicine
distilled prediction:candidate · insufficient_payloadconsensus · none
701
citations
affno abstractunlabeled
Endometrial cancer
Vicky Makker, Helen Mackay, Isabelle Ray‐Coquard, Douglas A. Levine, Shannon N. Westin, Daisuke Aoki +1 more
2021· review· en· Nature Reviews Disease Primers· Medicine
distilled prediction:candidate · metaepi_narrow+insufficient_payloadconsensus · none
691
citations
affunlabeled
Cancer of the cervix uteri
Adriana Bermúdez, Neerja Bhatla, Eric Leung
2015· article· en· International Journal of Gynecology & Obstetrics· Medicine
distilled prediction:candidate · noneconsensus · none
657
citations
affno abstractunlabeled
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
Domenica Lorusso, Yang Xiang, Kosei Hasegawa, Giovanni Scambia, Manuel Leiva, Pier Ramos-Elías +28 more
2024· article· en· The Lancet· Medicine
distilled prediction:candidate · metaepi_narrow+insufficient_payloadconsensus · none
349
citations
affunlabeled
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study
Ana Oaknin, Lucy Gilbert, Anna V. Tinker, Jubilee Brown, Cara Mathews, Joshua Z. Press +16 more
2022· article· en· Journal for ImmunoTherapy of Cancer· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
322
citations
affno abstractunlabeled
Adenocarcinoma: A unique cervical cancer
Lilian T. Gien, Marie-Claude Beauchemin, Gillian Thomas
2009· review· en· Gynecologic Oncology· Medicine
distilled prediction:candidate · metaepi_narrow+research_integrity+insufficient_payloadconsensus · none
271
citations

How this was built: Screen · Findings · About